• Daré Bioscience disclosed Phase 1 results for a topical sildenafil cream, with data set for presentation Oct. 9, 2026 at SMSNA.
• Study showed the cream produced much lower systemic drug exposure than oral sildenafil, supporting a localized delivery approach.
• Safety readout was clean, with only mild treatment-emergent adverse events reported and no serious events or discontinuations.
• Results underpin plans to advance the program toward an FDA 505(b)(2) filing as a potential treatment for female sexual arousal disorder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080915PRIMZONEFULLFEED9842153) on October 08, 2026, and is solely responsible for the information contained therein.